DYNAMIKA™ Platform: Smarter Engine for Clinical Trial Imaging

DYNAMIKA™ Platform: Smarter Engine for Clinical Trial Imaging

Today’s clinical trials are a race against complexity. As therapeutic areas become more specialized, and as multi-regional studies demand flawless coordination, the pressure to accelerate timelines without sacrificing data quality is intense. 

The traditional systems of managing logistics and review for clinical trial imaging, often fragmented, manual, and prone to delays, are no longer fit for purpose. Innovation isn’t optional; it’s the definitive path to drug development leadership and better patient outcomes.

For biopharma medical executives, operational leaders and clinical trial researchers, the challenge is clear: how do you harmonize global imaging data, integrate next-generation analytics, and ensure every endpoint is regulatory-ready, all within a single, secure ecosystem?

The answer lies in using smarter technology as an enabler to enhance the speed and accuracy of clinical trial imaging. 

IAG’s proprietary platform, DYNAMIKA™, for instance, is not merely a data viewer or a siloed software tool; it is a future-forward, cloud-native enterprise solution designed to fundamentally improve the management and analysis of medical imaging in drug development. Developed by an expert imaging CRO, DYNAMIKA™ unifies the entire imaging workflow, turning complex data logistics into a core competitive advantage.

The New Blueprint for Clinical Trial Imaging

DYNAMIKA™ serves as the single source of truth for all imaging data in a clinical trial program, from Phase I safety studies of an asset, through global efficacy phase II studies and post-marketing projects, including critical real-world evidence (RWE) initiatives.

Uniquely, DYNAMIKA™ architecture is such that every trial is part of the same infrastructure and it is not run on a replica of software in its individual silo. Thus, the full flow of imaging data centers around the asset, allowing the Drug Developers to connect the dots.

From the Sponsor point of view, the platform’s core architecture delivers on the promise of operational excellence, providing a robust, scalable infrastructure that handles data from global sites with efficiency and compliance. This end-to-end management approach is crucial for modern trials that often rely on complex patient stratification or additional analytics that are deployed post-hoc on the already acquired images. These are in addition to the regulatory required endpoints.

DYNAMIKA™ essential features

• Centralized Data Management: Unifies and manages global imaging data within a single, secure cloud platform.
• Radiological Review: Integrates expert review processes directly into the platform.
• Global Expertise: Connects a network of global specialists participating in data review or adjudication regardless of their geographic location.
• AI-Enabled Processes: Utilizes Artificial Intelligence workflow to support image analysis and informative insights.
• Streamlined Site Training: Simplifies the onboarding process for participating sites.
• Real-time Quality Control (QC): Automates checks instantly to ensure high image data quality, at the time of image upload. Then additionally gives a human expert possibility for a QC check.
• Minimizes Administrative Burden: Reduces manual tasks that typically slow down trial progress.
• Ensures Data Integrity: Maintains accuracy and consistency throughout every step of the workflow, while tracking every action through FDA-required audit trail.
• Seamless, Audit-Ready Data Trail: Provides full traceability and confidence for regulatory submissions.

From Pixels to Predictive Power

What truly sets DYNAMIKA™ and IAG apart is its deep understanding and smart use of Artificial Intelligence (AI) tool in clinical trials. We view AI not as a separate tool, but as an embedded co-pilot for advanced image analysis.

The platform is purpose-built to leverage AI imaging models and machine learning algorithms to generate objective, quantifiable data that traditional qualitative reads often miss.

This level of detail is delivered by providing standardized image assessments across a spectrum of therapeutic indications for smarter decisions, quicker studies, and reliable trial endpoints. Whether in complex oncology trials, rapidly evolving immunology research, or nuanced neurology studies, DYNAMIKA™ AI-powered analytics ensure that every measurement is reproducible, objective, and globally consistent, driving the precision required for personalized medicine.

Accelerating Timelines with Regulatory-Grade Confidence

In the high-stakes world of drug development, speed and compliance must go hand-in-hand. DYNAMIKA™ is engineered to drastically improve trial efficiency by transforming labor-intensive processes into automated, auditable workflows by:

• Accelerated Radiological Reading: Speeds up the central review process.
• Automation of Routine Tasks: Supports expert readers by handling repetitive, administrative work.
• Instant Discrepancy Flagging: Immediately identifies potential issues to maintain quality.
• Minimized Inter-Reader Variability: Ensures consistency and standardization across all expert reviews.
• Real-Time Visibility and Central Monitoring: Allows stakeholders to instantly track site and reader performance.
• Empowers Timely, Informed Decisions: Facilitates quick assessments, including critical go/no-go decisions.
• Eliminates Cycle Completion Delays: Enables decision-making without waiting for traditional, long review cycles.

DYNAMIKA™ is developed in compliance with global standards, including 21 CFR Part 11 and ISO 13485, certifying its infrastructure is built for ultimate data security and compliance. This focus on meticulous regulatory readiness means the imaging endpoints delivered are reliably regulator-ready, AI-enabled trial processes.

Global Reach, Integrated Expertise

A powerful platform is only as effective as the expertise behind it. IAG is an imaging CRO that couples DYNAMIKA™ with a global network of radiology and therapeutic experts. These seasoned professionals are deeply integrated into the platform’s workflow, designing custom clinical trial protocols based on specific trial requirements, overseeing data quality, and performing expert central review.

This combination of proprietary technology and human scientific insight means IAG can deploy advanced methodologies in real-time, leveraging the platform’s flexibility to support innovative trial designs, such as umbrella and basket trials. This integrated approach ensures that the output is not just data, but actionable evidence that strengthens a product’s value story.

A Strategic Enabler for Tomorrow’s Therapies

Dynamika is a strategic enabler for life sciences companies committed to pushing the boundaries of therapeutic innovation. It consolidates the required elements for successful imaging trials: global data logistics, state-of-the-art imaging analytics, and regulatory integrity.

By choosing a platform that is already ahead of the curve, sponsors gain an immediate operational and scientific edge. Dynamika empowers biopharma to leverage the full potential of clinical trial imaging, moving faster, minimizing risk, and delivering novel therapies to patients with greater confidence and speed.

You can learn more about how IAG delivers standardized image assessments across a spectrum of therapeutic indications for reliable trial endpoints, take a look at this video or reach out to our team.  

About Image Analysis Group (IAG)

Image Analysis Group (IAG) is a global imaging clinical research organization (iCRO) focused on de-risking and accelerating drug development through advanced imaging science and AI. IAG designs and runs imaging-centric clinical trials across oncology, immunology, neurology, rare diseases, musculoskeletal conditions, fertility and women’s health, partnering closely with biotech and pharma sponsors from early proof-of-concept through pivotal and real-world evidence studies.

Through its proprietary, cloud-native DYNAMIKA™ platform, IAG integrates centralized imaging workflows, blinded independent review, expert readers and AI-powered imaging biomarkers to deliver high-quality, regulator-ready imaging endpoints and decision-enabling insights that optimize trial design, reduce operational risk and unlock the full value of imaging data.